NASDAQ:ONVO Organovo (ONVO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Organovo Stock (NASDAQ:ONVO) 30 days 90 days 365 days Advanced Chart Get Organovo alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.66▼$15.2452-Week Range N/AVolume243,634 shsAverage Volume617,505 shsMarket Capitalization$3.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California. Read More Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address ONVO Stock News HeadlinesDriven! The Onvo L60 Is China’s Best Tesla Model Y Killer to DateMay 18, 2025 | msn.comTwo new option listings and one option delisting on April 24thApril 25, 2025 | markets.businessinsider.comA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it. | Porter & Company (Ad)VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ MarketApril 24, 2025 | globenewswire.comOrganovo announces VivoSim to carry forward 3D bioprinting, legacy techApril 23, 2025 | markets.businessinsider.comOrganovo Holdings, Inc. Announces Name Change to VivoSim Labs, Inc. and New Ticker Symbol "VIVS"April 23, 2025 | quiverquant.comQVivoSim to Carry Forward Organovo 3D BioprintingApril 23, 2025 | globenewswire.comOrganovo expects to meet requirements for continued listing on NasdaqApril 2, 2025 | markets.businessinsider.comSee More Headlines ONVO Stock Analysis - Frequently Asked Questions How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) posted its quarterly earnings results on Wednesday, February, 19th. The medical research company reported ($2.28) EPS for the quarter, topping the consensus estimate of ($2.52) by $0.24. The medical research company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Organovo had a negative net margin of 10,151.64% and a negative trailing twelve-month return on equity of 346.26%. When did Organovo's stock split? Organovo shares reverse split on Friday, March 21st 2025.The 1-12 reverse split was announced on Wednesday, March 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organovo investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), Brainstorm Cell Therapeutics (BCLI), AST SpaceMobile (ASTS) and Virgin Galactic (SPCE). Company Calendar Last Earnings2/19/2025Today7/02/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONVO CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($10.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.67 million Net Margins-10,151.64% Pretax Margin-10,150.00% Return on Equity-346.26% Return on Assets-187.53% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio1.72 Sales & Book Value Annual Sales$122 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares1,701,000Free Float14,794,000Market Cap$3.47 million OptionableOptionable Beta1.13 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ONVO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.